SEC Form 4 · accession 0001209191-19-017933
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Schoenberg
Officer — Chief Medical Officer
Period of report
Mar 4, 2019
Accepted (ET)
Mar 7, 2019 · 9:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Mar 4, 2019 | M | 1,042 | — | A | 6,329 | D | |
| Ordinary SharesF2 | Mar 6, 2019 | S | 1,991 | $37.30 | D | 4,338 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units (RSUs)F1,F3 | — | Mar 4, 2019 | M | 1,042 | D | — | — | Ordinary Shares | 1,042 | 7,292 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- F3On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years, with the issuance of the underlying shares for the March 4, 2019 installment delayed until March 5, 2019.